Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opnurasib in KRAS G12C+ NSCLC with Brain Metastases
NCT05999357Phase 2Withdrawn
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of opnurasib in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Primary endpoint: Brain Metastases Overall Response Rate up to 24 months. Planned start Apr 2024; status: withdrawn.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05999357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999357.